Suscribirse

Usefulness of the plasma glucose concentration-to-HbA1c ratio in predicting clinical outcomes during acute illness with extreme hyperglycaemia - 04/02/17

Doi : 10.1016/j.diabet.2016.07.036 
Y.-W. Su a, b, C.-Y. Hsu b, c, d, e, f, Y.-W. Guo g, H.-S. Chen a, b,
a Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan 
b Department of Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan 
c Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan 
d Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan 
e Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 
f Division of Cardiology and Cardiovascular Research Center, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan 
g Department of Medicine, Taipei City Hospital, Zhongxing Branch, Taipei, Taiwan 

Corresponding author. Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Aims

To evaluate the correlation between the plasma glucose-to-glycated haemoglobin ratio (GAR) and clinical outcome during acute illness.

Methods

This retrospective observational cohort study enrolled 661 patients who visited the emergency department of our hospital between 1 July 2008 and 30 September 2010 with plasma glucose concentrations>500mg/dL. Systolic blood pressure, heart rate, white blood cells, neutrophils, haematocrit, blood urea nitrogen, serum creatinine, liver function and plasma glucose concentration were recorded at the initial presentation to the emergency department. Data on glycated haemoglobin over the preceding 6 months were reviewed from our hospital database. The glucose-to-HbA1c ratio (GAR) was calculated as the plasma glucose concentration divided by glycated haemoglobin.

Results

The GAR of those who died was significantly higher than that of the survivors (81.0±25.9 vs 67.6±25.0; P<0.001). There was a trend towards a higher 90-day mortality rate in patients with higher GARs (log-rank test P<0.0001 for trend). On multivariate Cox regression analysis, the GAR was significantly related to 90-day mortality (hazard ratio [HR] for 1 standard deviation [SD] change: 1.41, 95% confidence interval [CI]: 1.22–1.63; P<0.001), but not to plasma glucose (HR: 0.89, 95% CI: 0.70–1.13; P=0.328). Rates of intensive care unit (ICU) admission and mechanical ventilator use were also higher in those with higher GARs.

Conclusion

GAR independently predicted 90-day mortality, ICU admission and use of mechanical ventilation. It was also a better predictor of patient outcomes than plasma glucose alone in patients with extremely high glucose levels.

El texto completo de este artículo está disponible en PDF.

Keywords : Diabetes mellitus, Glucose-to-glycated haemoglobin ratio, Glycated haemoglobin, Stress-induced hyperglycaemia

Abbreviations : ANC, ANOVA, AUC, BUN, CI, CRP, ED, eGFR, GAR, HbA1c, Hct, HR, ICU, LDL-C, ROC, SD, TC, WBC


Esquema


© 2016  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 43 - N° 1

P. 40-47 - février 2017 Regresar al número
Artículo precedente Artículo precedente
  • T-cadherin gene variants are associated with type 2 diabetes and the Fatty Liver Index in the French population
  • A. Nicolas, R. Aubert, N. Bellili-Muñoz, B. Balkau, F. Bonnet, J. Tichet, G. Velho, M. Marre, R. Roussel, F. Fumeron
| Artículo siguiente Artículo siguiente
  • Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials
  • M.B. Rehman, B.V. Tudrej, J. Soustre, M. Buisson, P. Archambault, D. Pouchain, H. Vaillant-Roussel, F. Gueyffier, J.-L. Faillie, M.-C. Perault-Pochat, C. Cornu, R. Boussageon

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.